Check for updates

RESEARCH ARTICLE

Anti-angiogenic effect of the combination low-dose sorafenib and EGCG in HCC-induced Wistar rats [version 1; peer review: 2 approved with reservations]

Andry Irawan[1], Erik Prabowo[1], Ignatius Riwanto[1], Wahyuni Lukita Atmodjo[2]

[1]Department of Digestive Surgery, Diponegoro University, Semarang, Central Java, Indonesia
[2]Department of Anatomy, Pelita Harapan University, Tangerang, Banten, Indonesia

Abstract

Background:
Sorafenib is an expensive standard drug used for advanced hepatocellular carcinoma. Its combination with epigallo-3-catechin gallate leads to a reduced cost but equally effective anti-angiogenic effect. Therefore, this study aims to assess the anti-angiogenic effect of standard-dose Sorafenib compared to the combination of low-dose Sorafenib and epigallo-3-catechin gallate.

Methods:
A total of 25 male Wistar rats (7-weeks-old) were randomly divided into 4 groups, namely Sham (K), Control (O), combination of low-dose Sorafenib and epigallo-3-catechin gallate group (X1), and standard-dose Sorafenib group (X2). All groups were injected with N-Nitrosodiethylamine 70 mg/kg bodyweight (BW) intraperitoneally for 10 weeks, except the Sham group. After the development of hepatocellular carcinoma, X1 and X2 were treated for 2 weeks. Subsequently, the level of vascular endothelial growth factor (VEGF) and expression of microvascular density was examined using liver tissues.

Results:
There was a significant difference (p=0.007) in the level of VEGF between the group X1 (106,682 ± 41,024) and X2 (214,5162 ± 67,71652). However, the differences in VEGF level of group X1 and X2 compared to group O (318,101 ± 55,078) were significantly lower, with values p=0.000136 and p=0.019, respectively. The expression of microvascular density between groups X1 (36 ± 4,416) and X2 (26,2 ± 4,55) was not significantly different. Meanwhile, a significant difference (p<0.05) was discovered when both groups were compared with group O (176 ± 19).

Conclusion:
The combination of low-dose Sorafenib with epigallo-3-catechin

Open Peer Review

Approval Status ✓ ? ?

	1	2	3
version 3 (revision) 21 Dec 2022	✓ view		? view
version 2 (revision) 21 Nov 2022	? view		
version 1 09 Mar 2022	? view	? view	

1. **Yefta Moenadjat** (iD), Universitas Indonesia, Jakarta, Indonesia

2. **Andree Kurniawan** (iD), Pelita Harapan University, Tangerang, Indonesia

3. **Alessandro Granito** (iD), Pelita Harapan University, Tangerang, Indonesia

Any reports and responses or comments on the article can be found at the end of the article.

gallate is superior in reducing the level of VEGF compared to standard-dose Sorafenib and is better than the control. Standard-dose Sorafenib as well as the combination of low-dose Sorafenib and epigallo-3-catechin gallate have similar effectivity to reduce the expression of microvascular density.

Keywords

Sorafenib, Epigallo-3-Catechin Gallate, Vascular Endothelial Growth Factor, Microvascular Density, N-Nitrosodiethylamine

Corresponding author: Andry Irawan (laparotomy85@gmail.com)

Author roles: Irawan A: Conceptualization, Data Curation, Formal Analysis, Funding Acquisition, Investigation, Methodology, Project Administration, Resources, Software, Supervision, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Prabowo E**: Conceptualization, Data Curation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Riwanto I**: Conceptualization, Data Curation, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Atmodjo WL**: Formal Analysis, Resources, Supervision, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing

Introduction

Hepatocellular carcinoma (HCC) is the most common primary type of liver cancer. In 2013, the prevalence of liver and bile duct cancer in a developed country like the United States was 30,640.[1,2] Meanwhile, a high incidence of HCC was discovered in South and East Asia, Central and West Africa, Melanesia, and Micronesia/Polynesia. It has been estimated that there are more than 749,000 new cases of HCC in men and 226,000 in women every year.[3,4] In 2020, liver cancer was considered the sixth most common cancer and the third leading to cancer-related deaths in the world.[5]

Vascular endothelial growth factors (VEGF) play an essential role in HCC tumor growth. Several carcinogens and tumor promoters initiate inappropriate activation of nuclear factor kappa B (NF-kB), which mediates the inflammation process and tumorigenesis. Meanwhile, overexpression of VEGF increases blood vessels permeability, leading to the differences between oxygen flow and delivery. A high level of VEGF is also typical in chronic liver disease that often triggers HCC.[6,7] Micro-vessel density (MVD) is a tumor indicator of angiogenesis that needs to be examined in HCC since a higher level of MVD shows a poor prognosis. This high angiogenic activity can be inhibited through the administration of anti-angiogenic drugs.[8]

The most common management of HCC for operable cancers is liver resection, while chemotherapy and targeted therapy are also used. It was discovered that 80% of HCC patients are diagnosed with advanced-stage or inoperable cancer. Systemic therapy with Sorafenib is required to change the condition at the operable stage. Sorafenib has been proven to be the first systemic therapy that successfully improved HCC patients' survival rate. It is an oral multi-kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR)-1, VEGFR-2, and VEGFR-3, thereby, reducing tumor angiogenesis. The disadvantages of Sorafenib treatment include high cost and approximately 30% of all patients responded to the treatment. Monotherapy of Sorafenib can cause several patient complaints, resistance, and high costs, therefore, when given in low-dose and combination with herbal medicines, the same effect is expected which is more affordable in price.[9–12]

Epigallocatechin-3-gallate (EGCG) is an active ingredient that was proven to prevent the growth of blood vessels in experimental animals. Its mechanism of action is by inhibiting urokinase and tyrosine kinase, which activates VEGF, epidermal growth factor (EGF), and fibroblast growth factor (FGF).[13] In 2005, a previous study in Japanese stated that EGCG induces both *in vitro* and *in vivo* liver cell apoptosis to improve the prognosis of HCC. *In vitro* studies showed that the effective concentration of EGCG varies from 1 to 100 mol/L. According to pre-clinical studies that were carried out in rats, only less than 5% of oral catechin taken as a constituent of tea can reach systemic circulation, therefore, intraperitoneally administration is considered more effective. EGCG is the right choice to be combined with Sorafenib in advanced HCC, which uses the synergism of the two drugs. This combination can lead to similar effects as the Sorafenib standard dose.[14,15]

Therefore, this study aims to investigate the effectiveness of anti-angiogenic activity between Sorafenib standard dose and the combination of low dosage Sorafenib with EGCG. It was presented in adherence to the checklist of ARRIVE reporting guidelines.

Methods

Induction of HCC in animals and experimental design

This study used a randomized control trial post-test only design method (Figure 1). A total of 25 male Wistar rats (PT Biomedical Technology Indonesia), which were 7 weeks old with bodyweight 200–250 grams were placed in a cage with a controlled temperature of 22°C under 12 hours of light and dark cycle. The rats were given free access to food with AIN76 standard dietary formula for rodents, which was 67.7% carbohydrates, 11.5% lipids, and 20.8% protein from the Food Engineering Laboratory, IPB, Bogor, Indonesia, purchased from PT Surya Science and Beverages.

Diethyl-Nitrosamine (DEN) (N0756) with a molecular weight of 102.14 and Epigallocathecin-3-O-Gallate (Y0001936; primary pharmaceutical grade standard) with a molecular weight of 458.37 was purchased from Sigma-Aldrich. While, each tablet of Sorafenib contains 200 mg as Tosylate (Nexavar).

This study followed the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals and was approved by Mochtar Riady Institute for Nanotechnology Ethics Committee (MRIN EC) with protocol number 2101001-AS06. The inclusion criteria were healthy and active 7-week-old male Wistar rats weighing 200–250 grams, while unhealthy male Wistar rats with anatomical anomalies are excluded. During the experiment, any infected or dead Wistar rats were also dropped out.

The sample size was calculated using the degree of freedom (Minimum and Maximum sample) formula. Rats were randomized and allocated into 4 groups, consisting of 7 rats in each group, except the control (K) group that contained

Figure 1. Consolidated report. DEN: Diethyl-Nitrosamine, EGCG: Epigallocatechin-3-gallate, MVD: Micro-vessel density, VEGF: Vascular endothelial growth factor.

4 rats, with a minimal sample size of three. Subsequently, DEN was injected intraperitoneally in the abdominal area below the umbilicus on 21 rats for two treatment groups and a control group, with 70 mg/kg BW/week for 10 weeks.[16,17] After 10 weeks, all rats were randomly divided into 4 groups, namely sham (K), Sorafenib 5 mg/kg BW + EGCG 5 mg/kg BW (X1), Sorafenib 15 mg/kg BW (X2), and without treatment (Group O). Group K was injected with saline for 10 weeks parallel with other groups. After the administration of DEN, group O was sacrificed, and a pathologist carried out a histopathological examination of liver tissue to show the formation of HCC. During the examination, anaplastic cells, oval nucleus, pleomorphic, coarse chromatin, and nucleolus invasive growth into stroma were observed, which confirmed HCC.

Sorafenib was dissolved in a maximum of 1.5 mL saline (maximum 10 mL/kg BW/day) and administered orally at a dose of 5 mg/kg BW and 15 mg/kg BW. Subsequently, EGCG 5 mg/kg BW/day was dissolved in approximately 1.5 mL saline (maximum 20 mL/kg BW/day) and administered by intraperitoneal injection once a day for 14 days. The sham

Figure 2. Macroscopic Liver tissue after 10 weeks of Diethyl-Nitrosamine (DEN) 70 mg/kg BW intraperitoneal injection. Group X1, X2, and O present multiple white nodules (White arrow); group (K) did not develop any nodules.

group (K) was administered a saline solution orally and intraperitoneally, while the sorafenib-only group (X2) received intraperitoneal saline and oral Sorafenib. Meanwhile, the combination group of EGCG and Sorafenib (X1) received intraperitoneal EGCG and oral Sorafenib and the bodyweight of the rats was measured once a week. At the end of the experiment, the rats were sacrificed, exsanguination was done on deeply anesthetized animals with ketamine 80 mg/kg BW and xylazine 100 mg/kg BW intramuscularly to ameliorate any suffering, and the liver tissues were resected and examined microscopically. Moreover, a veterinarian carried out a necropsy when any rat died during the experiment to investigate the cause of death investigate the cause of death (Figure 2).

In liver tissue, VEGF was evaluated using an enzyme-linked immunosorbent assay (ELISA) quantitative methods, while MVD was calculated using Immunohistochemistry (IHC). The intensity and area of sinusoidal endothelial staining were measured quantitatively using a microscope at $100\times$ magnification. Furthermore, the hot spots from the immunohisto-chemistry were selected using the "color selection" function and the "area/density (intensity)" function (ImageJ, RRID: SCR_003070) to calculate the values.

ELISA for tissue VEGF

To prepare lysate from tissue, tissue of interest was dissected with clean tools. Dissected tissue was placed in microcentrifuge or Eppendorf tubes. Lysis buffer consisting of NP-40 buffer, sodium chloride, NP-40, Tris pH 8.0, and Triton X-100 or NP-40) was added to 5 mg of tissue and homogenized rapidly. Next, it was centrifuged at 4°C for 20 minutes. After carefully removing the tubes and placing them on ice, any supernatant was aspirated, and the pellet were discarded.[18,19]

A Bradford, a Lowry, or a bicinchoninic acid (BCA) assay was conducted to calculate protein concentration. Bovine Serum Albumin (BSA) is usually used as a standard protein. Each sample was frozen at -20°C for immunoprecipitation. 200μL of 1X Bradford reagent, 5 μL of BSA, and 30 μL of the unknown sample were added to each test tube. Absorbance was determined using sipper or individual cuvettes at 595 (VIS lamp).

All standards and samples were prepared twice as recommended and stored at room temperature. Each well containing standard and sample were incubated for 2.5 hours at room temperature. The washing process using 300 μL of Wash Buffer was repeated four times. All liquid was eliminated after each step to achieve the best result. After the last wash, the plate was inverted and blotted using a paper towel.

Approximately 100 μL of $1\times$ Detection Antibody was titrated and incubated at room temperature for one hour. All liquid was removed, 100 μL of Streptavidin solution was added and incubated at room temperature for 45 minutes. Approx-imately 100 μL of TMB One-Step Substrate Reagent (Item H) was added and incubated in dark condition for 30 minutes. Lastly, 50 μL of Stop Solution (Item I) was added and absorbance was recorded at 450 nm.

Immunohistochemistry for MVD

Deparaffinization was done in incubator at 60°C for 45 minutes, followed by deparaffinization in xylene for 10 minutes. Next, 96% ethanol, 80% ethanol, and 70% ethanol were subsequently added to the formalin-fixed paraffin-embedded tissue for 5 minutes. Tissue was washed using distilled water. Antigen retrieval buffer (citrate buffer + tween) was placed into a jar and microwaved in full power for 20 minutes. The jar was removed and chilled on ice for 20 minutes.

Several drops of Hydrogen Peroxide Block were added to the section, incubated for 10 minutes, and rinsed two times in buffer. Protein Block was then added, incubated for 10 minutes, and rinsed once in buffer. Primary MVD polyclonal antibody (MBS 2520154) was added (1:100) in PBS-T, incubated in 4°C for 2 hours, and rinsed four times in buffer. A

Biotinylated Goat Anti-Polyvalent was added, incubated for 10 minutes, and rinsed four times in buffer. Streptavidin Peroxidase was added, incubated for 10 minutes, and rinsed four times in buffer.

Approximately 30 μL of DAB Chromogen was applied into 1.5 mL of DAB Substrate. It was incubated for 3 seconds and rinsed four times in buffer. Next, Hematoxylin was used as a counterstain, incubated for 20 minutes, and rinsed in tap water. Tissues were dehydrated using 70% ethanol, 80% ethanol, and 96% ethanol, each for 1 minute. The samples were observed under 10×, 40×, and 100× magnification.[20] For MVD, the Spearman's correlation coefficient (rho) was 0.93 (p < 0.01), while intra-observer agreement (Kappa) were 0.88 for cut-off using mean.[20,21]

Statistical analysis
All data were expressed as mean ± standard deviation of the mean. The statistical analysis was carried out using SPSS 28 (IBM SPSS Statistics, RRID:SCR_019096). All data were normally distributed and the comparisons between groups were analyzed using ANOVA. *Post hoc* analysis using the least significant difference (LSD), where a p-value < 0.05 was considered statistically significant.

Results
This study showed that the Sorafenib-only group effectively reduced VEGF tissue level better than without the treatment group. However, there was no significant difference in reducing MVD expression compared to the combination of low-dose Sorafenib and EGCG group, which indicated better overall results than the Sorafenib-only group. During the experiment, 9 rats died due to pulmonary hemorrhage and one rat died with irregular lung surface.

A total of 13 rats survived the 11 weeks of the experiment, although some looked unhealthy. One group reached the minimum sample size based on the calculation of the degree of freedom, the Institutional Animal Care and Use Committee (IACUC) Guidebook, and the World Health Organization (WHO). At the end of the experiment, the whole

Figure 3. The validation of HCC. Microscopic 40× magnification on non-induced Diethyl-Nitrosamine (DEN) group: (A, Group K) normal hepatocyte; comparing graphic on DEN induced group: (B, Group O) Bile Duct hyperplasia (Black square area); (C, Group X1) Hyperchromatic cells (black-arrow) and (D, Group X2) Prominent cell (thin-arrow), Hyperchromatic cell (thick black – arrow), Ballooning degeneration (Blue-Arrow). *HT, Hepatocyte; PT, Porta tract.*

Figure 4. The tissue VEGF levels. There was significant difference in levels of VEGF in group X1 compared to X2 (*). Between group X1 and O, VEGF was significantly different (**). Between group X2 and O, VEGF was significantly different (***) ($p < 0.05$).

group of mice was terminated according to the euthanasia techniques based on IACUC and the American Veterinary Medical Association (AVMA) Guidelines.

Data characteristic

The Shapiro-Wilk test results were used to calculate the mean and the distribution of the rats' body weight data and a $p > 0.05$ was obtained for all groups. Homogeneity test results with Levene's test obtained $p = 0.978$, which showed that the data obtained is homogeneous.

From the 16 sample slides examined, it was discovered that the tumor growth was solid with anaplastic cells having round, oval, pleomorphic nuclei, coarse chromatin, and prominent nucleolus that grows invasively into the stroma (Figure 3).

VEGF values

The mean VEGF values (Figure 4) between group Sorafenib 5 mg/kg BW + EGCG 5 mg/kg BW (X1) (106,682 $\pm$ 41,024) and group Sorafenib 15 mg/kg BW (X2) (214,5162 $\pm$ 67,717) had significant difference ($p < 0.05$), which showed that group X1 had the strongest effect in reducing VEGF values. Furthermore, the VEGF values between group X1 and the group without treatment (O) (318,101 $\pm$ 55,078) was significantly different ($p < 0.05$). A similar result was seen since VEGF values between group X2 and O was significantly different ($p < 0.05$).

MVD expression

MVD evaluation was carried out using $10\times$ and $40\times$ magnification to measure the intensity and area of sinusoidal endothelial staining (Figure 5). Subsequently, the hot spots from the immunohistochemistry were selected, and values were calculated. The mean MVD expression between the group Sorafenib 5 mg/kg BW + EGCG 5 mg/kg BW (X1) (36 $\pm$ 4.416) and group Sorafenib 15 mg/kg BW (X2) (26.2 $\pm$ 4.55) had no significant difference. Based on the results, MVD expression (Figure 6) between all groups and group O (176 $\pm$ 19) showed a significant difference ($p < 0.05$).

Discussion

This study showed that the benefits of the combination of Sorafenib and EGCG are the same as an anti-neoplastic drug, which is as effective as anti-angiogenic. The results of VEGF values between 2 groups, namely the combination group Sorafenib 5 mg/kg BW and EGCG 5 mg/kg BW (X1) compared with Sorafenib 15 mg/kg BW alone (X2) showed that

Figure 5. The MVD expression on microscope 10× (left side) and 40× magnification (right side): (A-B) (Group Sham) no finding of "Hot Spot" area on hepatocyte endothelial sinusoid; (C-D) (Group O) showed brown spot (black-arrow); (E-F) (Group X1) and (G-H) (Group X2) we found the same result (Black-Arrow). All three groups showed a "hot spot" area, which means there were positive results.

both treatments can reduce VEGF values. However, the X1 group was significantly more potent in decreasing VEGF value compared to group X2. This has exceeded the expectations, where the combination of low-dose Sorafenib and EGCG was more effective than only standard-dose Sorafenib. This indicated that Sorafenib and EGCG act synergistically with strengthening effect in anti-angiogenesis.

In vivo and *in vitro* studies have proved the effect of EGCG as a chemo-preventive, anti-angiogenic, anti-invasive, anti-proliferative, anti-inflammatory, and antioxidant substance. It was shown that EGCG blocks NF-kB activation by inhibiting IκBα degradation and the mitogen-activated protein kinase (MAPK) pathway. Meanwhile, downregulation of inducible nitric oxide synthase (iNOS) transcription and nitric oxide (NO) production from macrophages is dependent on NF-kB inhibition. It was reported that EGCG blocks NF-kB activation in human endothelial cells and inhibits monocyte chemotactic protein-1 (MCP-1) expression. Similarly, EGCG also prevents the apoptosis process by reducing mRNA expression of Bax and caspase 3 activity. It also inhibits cyclooxygenase-2 (COX-2) expression, proteasome-dependent

Figure 6. The MVD expression. There was no significant difference in expression of MVD between group X1 and X2, but both X1 and X2 were significantly different compared to the control group (O) (non-treatment group) with (p < 0.05).

degradation, MAPK pathways, and growth factor-dependent signaling, namely insulin-like growth factor-I (IGF-I), VEGF, and EGF.[22]

The results also suggested that several factors are responsible for the less effectiveness of the administration of Sorafenib as a single drug. Firstly, Sorafenib is accumulated in cancer cells, followed by an increase in the expression of enzymes to metabolize Sorafenib, which affects drug exposure. Thirdly, the presence or absence of tumor influences the concentration of Sorafenib and its primary metabolites based on assessing resistance to Sorafenib administration.[23]

MVD expression was significantly different between X1 and X2 groups compared to group O. This showed that the combination of low-dose Sorafenib and EGCG is also effective as standard-dose Sorafenib-only by decreasing MVD expression intratumorally. However, there is no significant difference in the discovery of MVD expression between the X1 and X2 groups. These are influenced by time length because the formation of MVD is affected by the growth of the capsule in the tumor. This is in line with the results by Kuczynski EA *et al.*, who showed that therapy with Sorafenib significantly inhibits MVD (p < 0.001 vs. controls), while the Sorafenib-resistant group showed no evidence of continued angiogenesis.[24] The evaluation of MVD expression is critical to determine the prognosis. According to Poon RTP *et al.,* MVD-CD34 tumors were the only significant predictor of disease-free survival in patients with HCC or tumor size < 5 cm.[25]

Although the result was different from the hypothesis, a very satisfying conclusion was successfully obtained. The combination of low-dose Sorafenib with EGCG had better effectiveness than the standard-dose of Sorafenib in lowering VEGF values and was equally effective in reducing MVD expression in Wistar rats induced by DEN. Based on the results, it was concluded that EGCG adds a supplementary anti-angiogenic effect for HCC. Therefore, the use of low-dose Sorafenib combined with EGCG acts as a more cost-effective therapy is recommended to potentially increase drug compliance. Similarly, it also provides a satisfying therapeutic effect for advanced HCC.

After 10 weeks of administering DEN 70 mg/kg, macroscopic gross liver tissues showed irregular surfaces and pale colors, the histopathologists also confirmed HCC characteristics. The length and dosage of DEN induction were in line with Atmodjo *et al.*, while the liver carcinogenesis or the beginning of HCC was recorded.[26] There was a force majeure event in the experimental animal since 9 rats were found dead. Meanwhile, 8 rats died because of pulmonary hemorrhage, and one died with irregular lung surface due to lung injury. The hypothesis of this study stated that the suppression of the immune system increases the probability of lung disorders due to respiratory infections or fibrosis, or early malignancy in the lungs when rats were injected with DEN.[27] This is because one rat that was not administered DEN died due to lung

hemorrhage. This can be explained by Kun MW *et al.*, who discovered the other cause of Wistar rat's lung problem was lung infection due to *A.Cantonensis.*[28] *M. Pulmonis* causes a different type of infection as explained by the study of Chawla *et al.*, which showed gross and histopathological discoveries of severe congestion of lungs with suppurative and necrotizing pneumonia.[29] Wang Y *et al.* also evaluated the induction effect of DEN in a rat model and discovered that the induced rat had liver dysfunction and damage, which is characterized by diffuse lesions with extensive interstitial inflammatory cell infiltration, alveolar edema, and bleeding. Meanwhile, minor injuries were discovered in the spleen, kidney, large intestine, heart, and other organs.[30] Atmodjo *et al.* also noted the same discoveries for lung hemorrhage.[26]

There are several limitations to this study, firstly, the unhealthy condition of the samples after 10 weeks of administration of DEN can affect the number of samples. This led to the consideration of the decision of earlier termination. Secondly, the method of administering EGCG was unclear with the best effectiveness, oral EGCG which is associated with poor absorption (<5% absorption rate). Therefore, the intraperitoneal injection method was used to administer EGCG. This study recommends further investigation whether the administration of EGCG in form of nanoparticles orally or parenterally can increase the absorption and bioavailability of EGCG in the intestine and plasma.[12,13]

Conclusion
The combination of low-dose Sorafenib with EGCG has a more potential anti-angiogenic effect in liver cancer by reducing VEGF values compared to the single standard-dose Sorafenib. It also has similar effectiveness as single standard-dose Sorafenib in reducing MVD expression compared to the control group. Meanwhile, further study on the anti-angiogenic effect of low-dose sorafenib combined with EGCG is recommended.

Data availability
Underlying data
Zenodo: Underlying data for 'Anti-angiogenic effect of the combination low-dose sorafenib and EGCG in HCC-induced Wistar rats.' https://doi.org/10.5281/zenodo.6044890.

This project contains the following underlying data:

- VEGF and MVD raw data.xlsx (dataset)

Reporting guidelines
Zenodo: ARRIVE checklist for 'Anti-angiogenic effect of the combination low-dose sorafenib and EGCG in HCC-induced Wistar rats.' https://doi.org/10.5281/zenodo.6044890.

Data are available under the terms of the Creative Commons Zero "No rights reserved" data waiver (CC0 1.0 Public domain dedication).

Authors' contributions
Conception and design: Andry Irawan, Erik Prabowo, Ignatius Riwanto

Administrative support: Andry Irawan, Erik Prabowo, Wahyuni Lukita Atmodjo

Provision of study materials or patients: Wahyuni Lukita Atmodjo

Collection and assembly of data: Andry Irawan

Data analysis and interpretation: Ignatius Riwanto, Wahyuni Lukita Atmodjo

Manuscript writing: All authors

Final approval of manuscript: All authors

Acknowledgements

References

1. Centers for Disease Control and Prevention (CDC): **Hepatocellular carcinoma - United States, 2001-2006.** *MMWR Morb. Mortal. Wkly. Rep.* 2010; **59**(17): 517–520.

2. Crissien AM, Frenette C: **Current management of hepatocellular carcinoma.** *Gastroenterol. Hepatol. (N Y).* 2014; **10**(3): 153–161.
   PubMed Abstract

3. Ferlay J, Shin HR, Bray F, *et al.*: **Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008.** *Int. J. Cancer.* 2010; **127**(12): 2893–2917.
   PubMed Abstract | **Publisher Full Text**

4. Shimizu M, Shirakami Y, Sakai H, *et al.*: **Chemopreventive potential of green tea catechins in hepatocellular carcinoma.** *Int. J. Mol. Sci.* 2015; **16**(3): 6124–6139.
   PubMed Abstract | **Publisher Full Text**

5. International Agency for Research on Cancer: *Liver.* World Health Organization; 2020. Accessed: January 30, 2021.
   Reference Source

6. Jain RK, Tong RT, Munn LL: **Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model.** *Cancer Res.* 2007; **67**(6): 2729–2735.
   PubMed Abstract | **Publisher Full Text**

7. Amarapurkar AD, Amarapurkar DN, Vibhav S, *et al.*: **Angiogenesis in chronic liver disease.** *Ann. Hepatol.* 2007; **6**: 170–173.
   Publisher Full Text

8. Bösmüller H, Pfefferle V, Bittar Z, *et al.*: **Microvessel density and angiogenesis in primary hepatic malignancies: Differential expression of CD31 and VEGFR-2 in hepatocellular carcinoma and intrahepatic cholangiocarcinoma.** *Pathol. Res. Pract.* 2018; **214**(8): 1136–1141.
   PubMed Abstract | **Publisher Full Text**

9. Sun HC, Tang ZY: **Angiogenesis in hepatocellular carcinoma: the retrospectives and perspectives.** *J. Cancer Res. Clin. Oncol.* 2004; **130**: 307–319.
   PubMed Abstract | **Publisher Full Text**

10. Llovet JM, Ricci S, Mazzaferro V: **Sorafenib in advanced hepatocellular carcinoma.** *N. Engl. J. Med.* 2008; **359**(4): 378–390.
    Publisher Full Text

11. MacGregor JL, Silvers DN, Grossman ME, *et al.*: **Sorafenib-induced erythema multiforme.** *J. Am. Acad. Dermatol.* 2007; **56**: 527–528.
    PubMed Abstract | **Publisher Full Text**

12. Cao Y, Cao R: **Angiogenesis inhibited by drinking tea.** *Nature.* 1999; **398**(6726): 381.
    PubMed Abstract | **Publisher Full Text**

13. Fassina G, Vene R, Morini M, *et al.*: **Mechanism of inhibition of tumor angiogenesis and vascular tumor growth by epigallocatechin 3 gallate.** *Clin. Cancer Res.* 2004; **10**: 4865–4873.
    PubMed Abstract | **Publisher Full Text**

14. Li Y, Chang SC, Goldstein BY, *et al.*: **Green tea consumption, inflammation and the risk of primary hepatocellular carcinoma in a Chinese population.** *Cancer Epidemiol.* 2011; **35**: 362–368.
    PubMed Abstract | **Publisher Full Text**

15. Nishikawa T, Nakajima T, Moriguchi M, *et al.*: **A green tea polyphenol, epigalocatechin-3-gallate, induces apoptosis of human hepatocellular carcinoma, possibly through inhibition of Bcl-2 family proteins.** *J. Hepatol.* 2006; **44**(6): 1074–1082.
    PubMed Abstract | **Publisher Full Text**

16. Nishida H, Omori M, Fukutomi Y, *et al.*: **Inhibitory effects of (−)-epigallocatechin gallate on spontaneous hepatoma in C3H/HeNCrj mice and human hepatoma-derived PLC/PRF/5 cells.** *Jpn. J. Cancer Res.* 1994; **85**: 221–225.
    PubMed Abstract | **Publisher Full Text** | **Free Full Text**

17. Arifin WN, Zahiruddin WM: **Sample Size Calculation in Animal Studies Using Resource Equation Approach.** *Malays. J. Med. Sci.* 2017; **24**(5): 101–105.
    PubMed Abstract | **Publisher Full Text**

18. Mathonnet M, Descottes B, Valleix D, *et al.*: **VEGF in hepatocellular carcinoma and surrounding cirrhotic liver tissues.** *World J. Gastroenterol.* 2006; **12**(5): 830–831.
    PubMed Abstract | **Publisher Full Text** | **Free Full Text**

19. Landriscina M, Cassano A, Ratto C, *et al.*: **Quantitative analysis of basic fibroblast growth factor and vascular endothelial growth factor in human colorectal cancer.** *Br. J. Cancer.* 1998; **78**(6): 765–770.
    PubMed Abstract | **Publisher Full Text** | **Free Full Text**

20. Viera AJ, Garrett JM: **Understanding interobserver agreement: the kappa statistic.** *Fam. Med.* 2005; **37**(5): 360–363.
    PubMed Abstract

21. Agnani B, Solanki R, Ansari M, *et al.*: **Prognostic Significance of Microvessel Density as Assessed by anti CD34 Monoclonal Antibody in Invasive Ductal Carcinoma of Breast.** *Asian Pac. J. Cancer Prev.* 2021; **5**(3): 75–79.

22. Jantan I, Ahmad W, Bukhari SNA: **Plant-derived immunomodulators: an insight on their preclinical evaluation and clinical trials.** *Front. Plant Sci.* 2015; **6**: 1–18.

23. Rochat B: **Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism.** *Clin. Parmacokint.* 2005; **44**: 349–366.
    PubMed Abstract | **Publisher Full Text**

24. Kuczynski EA, Lee CR, Man S, *et al.*: **Effects of Sorafenib Dose on Acquired Reversible Resistance and Toxicity in Hepatocellular Carcinoma.** *Cancer Res.* 2015; **75**: 2510–2519.
    PubMed Abstract | **Publisher Full Text**

25. Poon RT, Ng IO, Lau C, *et al.*: **Tumour microvessel density as a predictor of recurrence after resection of hepatocellular carcinoma: a prospective study.** *J. Clin. Oncol.* 2002; **20**: 1775–1785.
    PubMed Abstract | **Publisher Full Text**

26. Atmodjo WL, Larasati YO, Isbandiati D, *et al.*: **Curcuminoids Suppress the Number of Transformed-Hepatocytes and Ki67 Expression in Mice Liver Carcinogenesis Induced by Diethylnitrosamine.** *J. Can. Sci. Res.* 2018; **3**: 2.

27. Burkholder T, Foltz C, Karlsson E, *et al.*: **Health Evaluation of Experimental Laboratory Mice.** *Curr. Protoc. Mouse. Biol.* 2012; **2**: 145–165.
    PubMed Abstract | **Publisher Full Text**

28. Wun MK, Davies S, Spielman D, *et al.*: **Gross, microscopic, radiologic, echocardiographic and haematological findings in rats experimentally infected with *Angiostrongylus cantonensis.*** *Parasitology.* 2021; **148**(2): 159–166.
    PubMed Abstract | **Publisher Full Text**

29. Chawla S, Jena S, Venkatsan B, *et al.*: **Clinical, pathological, and molecular investigation of *Mycoplasma pulmonis*-induced murine respiratory mycoplasmosis in a rat (*Rattus norvegicus*) colony.** *Vet World.* 2017; **10**(11): 1378–1382.

30. Wang Y, Liang H, Jin F, *et al.*: **Injured liver-released miRNA-122 elicits acute pulmonary inflammation via activating alveolar macrophage TLR7 signaling pathway.** *Proc Natl Acad Sci U S A.* 2019; **116**(13): 6162–6171.

Open Peer Review

Current Peer Review Status: ❓ ❓

Version 1

Reviewer Report 23 September 2022

https://doi.org/10.5256/f1000research.120607.r151185

❓ **Andree Kurniawan** (iD)

Department of Internal Medicine, Faculty of Medicine, Pelita Harapan University, Tangerang, Indonesia

The authors have reported the basic science research regarding the the role of anti angiogenesis in HCC.

My comments are:

1. In the introduction may be added the recent update in HCC since there are emerging new data about anti angiogenesis and immunotherapy . may be added also the role of levantinib. Sorafenib nowadays is not a standard of care for advanced inoperable HCC. Atezo Bev was the standard of care.

2. Should be added also in the introduction the background rationale for this research since there are several studies about it already.

3. In the discussion should be added the implication for clinical practice the combination of experimental drugs. What is the implication for translation research from this data?

4. Advice for further basic research should be added, related to the limitations of this study.

5. In the discussion do not repeat the results, however, compare the results with other studies - similar results or different results ?

Is the work clearly and accurately presented and does it cite the current literature?
Partly

Is the study design appropriate and is the work technically sound?
Yes

Are sufficient details of methods and analysis provided to allow replication by others?
Yes

If applicable, is the statistical analysis and its interpretation appropriate?
Partly

Are all the source data underlying the results available to ensure full reproducibility?
Yes

Are the conclusions drawn adequately supported by the results?
Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: HCC, epidemiology, cancer, hematology

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 08 Nov 2022

Andry Irawan

Dear Dr Andree Kurniawan,

Thank you for allowing us to submit a revised draft of our manuscript titled *Anti-angiogenic effect of the combination low-dose sorafenib and EGCG in HCC-induced Wistar rats*. We appreciate the time and effort you have dedicated to providing your valuable feedback on our manuscript. We are grateful to the reviewer for their insightful comments on our paper. We have been able to incorporate changes to reflect most of the suggestions provided by the reviewer. We have highlighted the changes within the manuscript.

Here is a point-by-point response to the reviewer's comments and concerns.

1. In the introduction may be added the recent update in HCC since there are emerging new data about anti angiogenesis and immunotherapy may be added also the role of levantinib. Sorafenib nowadays is not a standard of care for advanced inoperable HCC. Atezo Bev was the standard of care.

Author's comment: We have incorporated the additional statement in the second last paragraph of the introduction.

2. Should be added also in the introduction the background rationale for this research since there are several studies about it already.

Author's comment: The research rationale has been stated in the 3rd paragraph of the

introduction.

3. In the discussion should be added the implication for clinical practice the combination of experimental drugs. What is the implication for translation research from this data?

Author's comment: The combination of low-dose Sorafenib with EGCG has a more potential anti-angiogenic effect in liver cancer by reducing VEGF values compared to the single standard-dose Sorafenib. We can advance the research into human, but firstly we need to examine the toxicity effect in animal research.

4. Advice for further basic research should be added, related to the limitations of this study.

Author's comment: The advice for further studies has been mentioned in the limitation section of the discussion.

5. In the discussion do not repeat the results, however, compare the results with other studies - similar results or different results?

Author's comment: The comparison with other studies has been incorporated in the 4th paragraph of the discussion.

We look forward to hearing from you in due time regarding the submission, responses, further questions, and comments you may have. Thank you.

Sincerely,
Andry Irawan

Competing Interests: The Authors declared no competing interests related to this study

Author Response 17 Dec 2022

Andry Irawan

Dear Dr. Yefta Moenadjat,

Thank you for allowing us to submit a revised draft of our manuscript. We have adjusted several texts and sentences based on your highlighted texts. We also attempted to register the experimental study; however, all animal study registries must be submitted before the research is done. We sincerely regret this matter, and our evaluation will be for the following animal study.

We look forward to hearing from you regarding the submission, responses, questions, and comments you may have. Thank you.

Sincerely,

Andry Irawan

Competing Interests: We declared no competing interests within this study.

Reviewer Report 22 June 2022

?

Yefta Moenadjat iD

Faculty of Medicine, Department of Surgery Cipto Mangunkusumo General Hospital, Universitas Indonesia, Jakarta, Indonesia

1. The abstract
- Abstract reflects the information of the content. The first statement in the background was not in line with the texts elsewhere in the content. In addition, the study was not dealing with the cost and benefit but the efficacy. Then why do the authors put an irrelevant statement here?
- The method section in the abstract comprises a brief description of the study design and PICO. Consider revising.
- In the results section of an abstract, it is better to provide the interpretation of the findings in the study rather than providing statistical analysis. In addition, it will be better to put an attribute (for instance, group I, II, II, and control) rather than X1, X2, confusing the readers.
- Results session: Please consider using English formatting correctly. English does not use a comma but a point for decimals.
- The abstract's conclusion differs from the conclusion written in the body and is not in line with the study's title and aim, which is focused on the anti-angiogenic effect. Therefore, consider being consistent with it.

2. Introduction
- The second paragraph:
  - Are the statement in the first three sentences referred to as the same reference as the fourth sentence?
  - There is an interplay of some factors, including VEGF inducing cancer - including HCC - and not solely VEGF. Consider elaborating a little bit regarding this. It does not matter if the authors solely focus on VEGF.
  - Consistency is essential in scientific publication. Therefore, consider using 'level' consistently instead of using a different term of 'concentration' or 'values' in this manuscript.
- The third paragraph:
  - Is surgery the most common procedure, or is it a primary or definitive procedure?
  - The author stated: "...while chemotherapy and targeted therapy are also used." The question is: Is it 'also used' or is it the protocol for the HCC?

- The fourth paragraph:
    - Instead of providing information from previous studies reporting improvement in the prognosis of HCC, the authors should propose the rationale for using this drug to suppress VEGF.
    - It is essential to answer the question of why use this drug.
    - Authors should provide information on why using the rat model. Particularly the HCC-induced model.
    - There is no information about using DEN in the background that presents the transparency of using DEN to induce HCC.
    - Consider providing such information about toxicity and carcinogenesis effect briefly. Not all readers know about this.
- The fifth paragraph:
    - The statement was not in line with the structure following the checklist. In addition, the link provided indicating the ARRIVE checklist is the same as provided in ARRIVE guidelines https://arriveguidelines.org/ but not specific for this study.

3. Methods
- Describe systematically and sequentially:
    - Study design, division of groups in randomization (including randomization process, random? who did the randomization? what was the instrument used for this purpose?)
    - Preparation of animals and pre-intervention treatment,
    - Intervention detail in each group,
    - Preparation of materials/materials.
- Next, the treatment consists of:
    - The carcinogenesis induction process. Who judges the successful induction, and how did it assess, showing that the intervention was successful? How long does it take to determine that the induction process was successful?
- Describe further detail of tumor-induced DEN characteristics that are similar to an HCC.
- This section does not explain when Sorafenib and ECGC are given. Either immediately or wait until the HCC induction procedure has been successful. Although, it was explained that the specimens were taken ten weeks after administering these two drugs.
- The authors did not describe the specific area of the taken specimen but 'liver tissue'. Was it taken from a tumor mass?
- Describe further detail of method in systematic order.

4. Results. Use the same terminology that commented in the introduction and method. Consider providing the findings, but not the interpretation.
5. Discussion. Use the same terminology that commented in the introduction and method.
6. Conclusion. Use the same terminology that commented in the introduction and method.

Is the work clearly and accurately presented and does it cite the current literature?
Partly

Is the study design appropriate and is the work technically sound?
Partly

Are sufficient details of methods and analysis provided to allow replication by others?

Partly

If applicable, is the statistical analysis and its interpretation appropriate?
Partly

Are all the source data underlying the results available to ensure full reproducibility?
Partly

Are the conclusions drawn adequately supported by the results?
Partly

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 22 Sep 2022
Andry Irawan

Dear Dr Yefta Moenadjat,

Thank you for allowing us to submit a revised draft of our manuscript titled *Anti-angiogenic effect of the combination low-dose sorafenib and EGCG in HCC-induced Wistar rats*. We appreciate the time and effort you have dedicated to providing your valuable feedback on our manuscript. We are grateful to the reviewer for their insightful comments on our paper. We have been able to incorporate changes to reflect most of the suggestions provided by the reviewer. We have highlighted the changes within the manuscript.

Here is a point-by-point response to the reviewer's comments and concerns.

1. THE ABSTRACT
- Abstract reflects the information of the content. The first statement in the background was not in line with the texts elsewhere in the content. In addition, the study was not dealing with the cost and benefit but the efficacy. Then why do the authors put an irrelevant statement here?
- The method section in the abstract comprises a brief description of the study design and PICO. Consider revising.
- In the results section of an abstract, it is better to provide the interpretation of the findings in the study rather than providing statistical analysis. In addition, it will be better to put an attribute (for instance, group I, II, II, and control) rather than X1, X2, confusing the readers.
- Results session: Please consider using English formatting correctly. English does not use a comma but a point for decimals.
- The abstract's conclusion differs from the conclusion written in the body and is not in line with the study's title and aim, which is focused on the anti-angiogenic effect.

> Therefore, consider being consistent with it.

Author's comment: *Thank you for your concern. We have revised the abstract section into a more relevant statement.*

2. INTRODUCTION

The second paragraph:

- Are the statement in the first three sentences referred to as the same reference as the fourth sentence?

Author's comment: Yes, they referred to the same reference.

- There is an interplay of some factors, including VEGF inducing cancer - including HCC - and not solely VEGF. Consider elaborating a little bit regarding this. It does not matter if the authors solely focus on VEGF
- Consistency is essential in scientific publication. Therefore, consider using 'level' consistently instead of using a different term of 'concentration' or 'values' in this manuscript.

Author's comment: *Thank you for your positive feedback. We have elaborated the interplay factors and revised the 'concentration' or 'values' into 'level' terms.*

The third paragraph:

- Is surgery the most common procedure, or is it a primary or definitive procedure?

Author's comment: Yes, surgery is the definitive treatment for HCC if it is operable

- The author stated: "...while chemotherapy and targeted therapy are also used." The question is: Is it 'also used' or is it the protocol for the HCC?

Author's comment: Yes, it is the protocol for unresectable HCC

The fourth paragraph:

- Instead of providing information from previous studies reporting improvement in the prognosis of HCC, the authors should propose the rationale for using this drug to suppress VEGF.
- It is essential to answer the question of why use this drug.

- Authors should provide information on why using the rat model. Particularly the HCC-induced model.
- There is no information about using DEN in the background that presents the transparency of using DEN to induce HCC.
- Consider providing such information about toxicity and carcinogenesis effect briefly. Not all readers know about this.

Author's comment: Thank you for your considerate question. We have incorporated all the questions stated above within the manuscript.

The fifth paragraph:

- The statement was not in line with the structure following the checklist. In addition, the link provided indicating the ARRIVE checklist is the same as provided in ARRIVE guidelines https://arriveguidelines.org/ but not specific for this study.

Author's comment: The ARRIVE checklist is available in the reporting guideline section. Zenodo: ARRIVE checklist for 'Anti-angiogenic effect of the combination low-dose sorafenib and EGCG in HCC-induced Wistar rats.' https://doi.org/10.5281/zenodo.6044890.

3. METHODS

Describe systematically and sequentially:
- Study design, division of groups in randomization (including randomization process, random? who did the randomization? what was the instrument used for this purpose?)

Author's comment: This study was a double-blind, randomized control trial. A laboratory analyst performed randomization into four groups.
- Preparation of animals and pre-intervention treatment,
- Intervention detail in each group,
- Preparation of materials/materials.

Author's comment: Thank you for your insightful comments. We have incorporated the additional statement in the methods section.
Next, the treatment consists of:
- The carcinogenesis induction process. Who judges the successful induction, and how did it assess, showing that the intervention was successful? How long does it take to determine that the induction process was successful?

Author's comment: An anatomical pathologist from Dr Mintoharjo Naval Hospital determined the successful induction under the microscope and required ten weeks to confirm the accomplishment of the induction.
- Describe further detail of tumor-induced DEN characteristics that are similar to an HCC.

Author's comment: We have elaborated on the similarity of the tumor-induced DEN and HCC characteristics.
- This section does not explain when Sorafenib and ECGC are given. Either immediately or wait until the HCC induction procedure has been successful. Although, it was explained that the specimens were taken ten weeks after administering these two drugs.

Author's comment: Sorafenib and ECGC were given until the HCC induction procedure was successful by the result from the anatomical pathologist successfully succeeded.
- The authors did not describe the specific area of the taken specimen but 'liver tissue'. Was it taken from a tumor mass?

Author's comment: Yes, we took the whole liver tissue-contained tumor masses
- Describe further detail of method in systematic order.

Author's comment: We have amended the method section more systematically.
We look forward to hearing from you in due time regarding the submission, responses, further questions, and comments you may have. Thank you.

Sincerely,
Andry Irawan

Competing Interests: We declared no competing interests within our study.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias

- You can publish traditional articles, null/negative results, case reports, data notes and more

- The peer review process is transparent and collaborative

- Your article is indexed in PubMed after passing peer review

- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research